131,200 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Springhill Fund Asset Management HK Co Ltd

Springhill Fund Asset Management HK Co Ltd bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 131,200 shares of the company’s stock, valued at approximately $3,091,000. Dyne Therapeutics makes up approximately 5.0% of Springhill Fund Asset Management HK Co Ltd’s holdings, making the stock its 11th largest holding. Springhill Fund Asset Management HK Co Ltd owned approximately 0.13% of Dyne Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $36,000. KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after buying an additional 978 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Dyne Therapeutics in the 4th quarter valued at approximately $257,000. Finally, Magnetar Financial LLC purchased a new position in Dyne Therapeutics during the fourth quarter worth $263,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 6,237 shares of company stock worth $77,760. Insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Robert W. Baird began coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Piper Sandler reduced their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Stock Down 12.1 %

Shares of DYN stock opened at $8.28 on Friday. The stock has a 50-day simple moving average of $12.81 and a 200 day simple moving average of $22.61. The stock has a market capitalization of $936.64 million, a P/E ratio of -2.33 and a beta of 1.21. Dyne Therapeutics, Inc. has a fifty-two week low of $8.15 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.